Ribo Consecutively Honored With Two Major Industry Awards
May 22, 2026 · Suzhou China
Lately, Suzhou Ribo Life Science Co., Ltd. (“Ribo”, 06839.HK) has received consecutive accolades. Following its recognition as one of the " TOP 50 Most Investable Companies in China's Healthcare Industry " at 2026 China Future Healthcare Conference, Ribo was further honored with the title of " World Finance Forum’s Sci-Tech Innovation Leading Enterprises" at The Ninth World Finance Forum Annual Conference and Dialogue of Continents 2026 High-Level Seminar. The consecutive awards not only demonstrated the industry and capital markets' high recognition of Ribo's innovation capabilities, platform & pipeline value and its commercialization potential, but also signifies that Ribo, as China's leading siRNA company, is accelerating its leadership in global siRNA competition.
These two honors collectively demonstrate the comprehensive strength of Ribo from different perspectives:
After a decade of development, the China Future Healthcare Conference has become a highly credible and influential innovative recognition benchmark in China's healthcare industry. This year's award ceremony integrates previous sub-categorizations such as Annual Leading Enterprises, Annual Outstanding Enterprises, and Annual Innovative Enterprises, and upgrades them into a comprehensive ranking covering both listed and unlisted entities for the first time - "TOP 50 Most Investable Companies in China's Healthcare Industry", and a sets up a tiered evaluation system encompassing four key dimensions: core business competitiveness, innovation capability, sustainable operational capacity, and recognition in the capital market. This year’s ranking includes 17 listed companies and 33 unlisted enterprises, spanning diverse sectors such as innovative pharmaceuticals, pharmaceutical equipment, AI-driven healthcare, high-end medical devices, medical services, brain science, and cell therapy. Ribo was ranked among the top performers based on its internationally leading differentiated siRNA pipeline, a globally integrated siRNA R&D system, and robust overseas clinical and business development capabilities.
The Ninth World Finance Forum Annual Conference and Dialogue of Continents 2026 High-Level Seminar was co-hosted by the Organizing Committee of the World Finance Forum（WFF）, the Center for BRICS and Global Governance(CBGG) and the Reinventing Bretton Woods Committee(RBWC), with the Financial Services Development Council(FSDC) as strategic partner, the conference has the theme “In Search of a New Anchor for Stability and Growth: How to Reshape and Adapt to the New World Economic and Financial Landscape in a Divided and Turbulent World”. The conference brings together representatives from government authorities, leading companies and academia for discussions on how to create certainty in an era of uncertainty, aiming to provide a high-level dialogue platform for policymakers, financiers, entrepreneurs, investors, innovators and scholars to share insights, pool wisdom and foster cooperation. During the award ceremony held at the event, Ribo, as the undisputed leader in China's siRNA sector, was honored with the title of World Finance Forum's Sci-Tech Innovation Leading Enterprises".
These two honors fully demonstrate Ribo's strategic foresight in innovation-driven, differentiated development, and globalization strategy. As a leading enterprise in China's siRNA sector, Ribo has established a robust core competitiveness that has earned dual recognition from both the industry and authoritative institutions. The global siRNA industry has now entered a new phase of explosive growth. Ribo has seized this historic development opportunity, consistently adhering to a patient-centric philosophy, focusing on innovation-driven growth, continuously expanding its international presence, and strengthening its comprehensive competitive capabilities.
In the future, Ribo will drive steady performance improvement through prudent operations, leverage sustainable development to empower long-term value growth, and facilitate the global dissemination of innovative made-in-China siRNA drugs to benefit patients worldwide.